Delivery Order SPE2DB20D7059-SPE2DB24FPYK4
Award Date
1/31/24
Potential Completion Date
2/1/24
Potential Value
$10K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Cencora, Inc.
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is for the procurement of HEMABATE 250 MCG/ML AMPULML, a specialty pharmaceutical product, with a potential value of $1,097.24 and a completion date of February 1, 2024. This award is not associated with any set-aside designation....
This federal contract award, valued at $7,061.26, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of HEMABATE 250 MCG/ML AMPUL/ML, a pharmaceutical product, with a completion date of January 23, 2024. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, including the Department of Defense (DoD) and Veterans Affairs...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,239.50, is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product. The contract has an ultimate completion date of January 22, 2025 and is a firm fixed-price contract. This contract does not have a set-aside designation, indicating it was competitively awarded....
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of HEMABATE 250 MCG/ML AMPULML. The award, valued at $6,555.04, is a firm fixed-price Delivery Order with a completion date of February 16, 2024. This contract does not have a set-aside designation, indicating it was competitively awarded. AmerisourceBergen holds a significant Indefinite Delivery...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $2,666.41, is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product. The contract is a firm fixed-price delivery order with an ultimate completion date of April 18, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
The Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a Firm Fixed Price delivery order contract (SPE2DB22D3011|SPE2DB24FQ0DX) valued at $5,522.91 to provide HEMABATE 250 MCG/ML AMPULML pharmaceutical products. The contract has a performance period through March 28, 2024 and was not set aside for any specific business type. Amerisourcebergen Drug Corp serves as a prime contractor to DLA Troop Support Medical, providing a wide range...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distributor AmerisourceBergen Corporation. The $8,777.92 firm fixed price delivery order is for the supply of HEMABATE 250 MCG/ML AMPULML, a prescription medication. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to AmerisourceBergen Drug Corp, valued at up to $999,999,999.00 and running through...
This federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a ceiling value of $23,749.20. The contract is a Firm Fixed Price Delivery Order with a period of performance through November 29, 2023. AmerisourceBergen, a major pharmaceutical distributor, holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division to provide a comprehensive...
This federal contract award, valued at $20,848.30, was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is a Delivery Order for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product. The award is a Firm Fixed Price contract with an ultimate completion date of January 11, 2022. This contract is not designated with a set-aside requirement, indicating it was awarded through full and open...
Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, has received a $2,350.56 firm fixed price delivery order from the Defense Logistics Agency (DLA) Troop Support Medical to supply 4562766251 HEMABATE 250 MCG/ML AMPULML. Performance will take place at Amerisourcebergen's headquarters in Conshohocken, Pennsylvania by November 9, 2023. No set-aside designation was applied to this order placed pursuant to DLA Troop Support Medical's provision of pharmaceuticals and medical...